Continue Your Education

Although there has been considerable progress in the treatment of early stage HER2+ breast cancer, there are still areas of unmet need. Specifically, there are patients that still go on to develop metastatic disease despite optimal neoadjuvant and adjuvant therapy. Moreover, a good percentage of these patients are relapsing in the CNS, despite the gains we have achieved with T-DM1 in the post neoadjuvant setting. In the metastatic setting, first line therapy with a taxane, trastuzumab and pertuzumab has become standard. However, with the approval of several other agents optimizing sequencing strategies remains an area of active investigation. Balancing side effects, dosing schedules as well as efficacy of these agents continues to be challenging. Patient goals of care are also being given a much more significant place in therapeutic decision making. Dr. Irene Kang, from University of Southern California Norris Comprehensive Cancer Center, and Dr. Charles Vogel, from Baptist Health South in Miami, Florida, discuss the newest information on data and supporting data leading to better selection of treatment for early stage and metastatic HER2+ breast cancer. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians Amedco LLC designates this live activity for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses Amedco LLC designates this activity for a maximum of .75 ANCC contact hours. Pharmacists and Pharmacy Technicians Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours. How to Get Your Certificate 1. Go to https://workshop-evaluator.herokuapp.com/evaluation/9344 2. Evaluate the meeting. 3. Print all pages of your certificate for your records. Questions? Email Certificate@AmedcoEmail.com Learner's Notification: https://bit.ly/3hUMhd6

Although there has been considerable progress in the treatment of early stage HER2+ breast cancer, there are still areas of unmet need. Specifically, there are patients that still go on to develop metastatic disease despite optimal neoadjuvant and adjuvant therapy. Moreover, a good percentage of these patients are relapsing in the CNS, despite the gains we have achieved with T-DM1 in the post neoadjuvant setting. In the metastatic setting, first line therapy with a taxane, trastuzumab and pertuzumab has become standard. However, with the approval of several other agents optimizing sequencing strategies remains an area of active investigation. Balancing side effects, dosing schedules as well as efficacy of these agents continues to be challenging. Patient goals of care are also being given a much more significant place in therapeutic decision making. Dr. Virginia Kaklamani, from MD Anderson Cancer Center, and Dr. Ruth O’Regan, from the University of Rochester, discuss the newest information on data and supporting data leading to better selection of treatment for early stage and metastatic HER2+ breast cancer. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians Amedco LLC designates this live activity for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses Amedco LLC designates this activity for a maximum of .75 ANCC contact hours. Pharmacists and Pharmacy Technicians Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours. How to Get Your Certificate 1. Go to https://workshop-evaluator.herokuapp.com/evaluation/9330 2. Evaluate the meeting. 3. Print all pages of your certificate for your records. Questions? Email Certificate@AmedcoEmail.com Learner's Notification: https://bit.ly/2Uqsrh1

Although there has been considerable progress in the treatment of early stage HER2+ breast cancer, there are still areas of unmet need. Specifically, there are patients that still go on to develop metastatic disease despite optimal neoadjuvant and adjuvant therapy. Moreover, a good percentage of these patients are relapsing in the CNS, despite the gains we have achieved with T-DM1 in the post neoadjuvant setting. In the metastatic setting, first line therapy with a taxane, trastuzumab and pertuzumab has become standard. However, with the approval of several other agents optimizing sequencing strategies remains an area of active investigation. Balancing side effects, dosing schedules as well as efficacy of these agents continues to be challenging. Patient goals of care are also being given a much more significant place in therapeutic decision making. Dr. Jane Meisel, from Emory University and Dr. Hatem Soliman, from Moffitt Cancer Center, discuss the newest information on data and supporting data leading to better selection of treatment for early stage and metastatic HER2+ breast cancer. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians Amedco LLC designates this live activity for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses Amedco LLC designates this activity for a maximum of .75 ANCC contact hours. Pharmacists and Pharmacy Technicians Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours. How to Get Your Certificate 1. Go to https://workshop-evaluator.herokuapp.com/evaluation/9250 2. Evaluate the meeting. 3. Print all pages of your certificate for your records. Questions? Email Certificate@AmedcoEmail.com Learner's Notification: https://bit.ly/3qAfw7N

Although there has been considerable progress in the treatment of early stage HER2+ breast cancer, there are still areas of unmet need. Specifically, there are patients that still go on to develop metastatic disease despite optimal neoadjuvant and adjuvant therapy. Moreover, a good percentage of these patients are relapsing in the CNS, despite the gains we have achieved with T-DM1 in the post neoadjuvant setting. In the metastatic setting, first line therapy with a taxane, trastuzumab and pertuzumab has become standard. However, with the approval of several other agents optimizing sequencing strategies remains an area of active investigation. Balancing side effects, dosing schedules as well as efficacy of these agents continues to be challenging. Patient goals of care are also being given a much more significant place in therapeutic decision making. Dr. Tiffany Traina, from Memorial Sloan Kettering Cancer Center and Dr. Lisa Carey, from the University of North Carolina, discuss the newest information on data and supporting data leading to better selection of treatment for early stage and metastatic HER2+ breast cancer. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians Amedco LLC designates this live activity for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses Amedco LLC designates this activity for a maximum of .75 ANCC contact hours. Pharmacists and Pharmacy Technicians Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours. How to Get Your Certificate 1. Go to https://workshop-evaluator.herokuapp.com/evaluation/9287 2. Evaluate the meeting. 3. Print all pages of your certificate for your records. Questions? Email Certificate@AmedcoEmail.com Learner's Notification: https://bit.ly/3xvlmtI

In this webinar, Dr. Mark Pegram, Medical Oncologist and Breast Specialist from Palo Alto, CA presents updates in extended endocrine therapy for HR+ breast cancer, including the most clinically-relevant data from the 2021 ASCO annual conference and national practice guidelines. Sponsored by Biotheranostics Inc., a Hologic company. Mark Pegram, MD is a Medical Consultant of Biotheranostics, Inc.

Although there has been considerable progress in the treatment of early stage HER2+ breast cancer, there are still areas of unmet need. Specifically, there are patients that still go on to develop metastatic disease despite optimal neoadjuvant and adjuvant therapy. Moreover, a good percentage of these patients are relapsing in the CNS, despite the gains we have achieved with T-DM1 in the post neoadjuvant setting. In the metastatic setting, first line therapy with a taxane, trastuzumab and pertuzumab has become standard. However, with the approval of several other agents optimizing sequencing strategies remains an area of active investigation. Balancing side effects, dosing schedules as well as efficacy of these agents continues to be challenging. Patient goals of care are also being given a much more significant place in therapeutic decision making. Dr. Nusayba A Bagegni, from Washington University in St. Louis, Alvin J. Siteman Comprehensive Cancer Center, and Dr. William J Gradishar, from Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the newest information on data and supporting data leading to better selection of treatment for early stage and metastatic HER2+ breast cancer. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians Amedco LLC designates this live activity for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses Amedco LLC designates this activity for a maximum of .75 ANCC contact hours. Pharmacists and Pharmacy Technicians Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours. How to Get Your Certificate 1. Go to http://workshop-evaluator.herokuapp.com/evaluation/9144 3. Evaluate the meeting. 4. Print all pages of your certificate for your records. Questions? Email Certificate@AmedcoEmail.com Learner's Notification: bit.ly/3wRNlDa

One question we always hear is, "What will change on Monday morning?" So, we designed a program to answer precisely that! During a live Q&A panel and discussion forum, leading physicians filter data from the 2021 ASCO Annual Meeting, address hot topics, and answer the questions that are on everyone's mind, focusing on Breast Cancer. Panelists Include: Dr. Kevin Kalinsky | Emory Winship Cancer Institute Dr. Ann Patridge | Dana Farber Cancer Institute Dr. Terry Mamounas | Orlando Health Dr. Kristina Mirabeau Beale | Genesis Care USA Dr. Foluso Olabisi Ademuyiwa | Washington University Abstracts and studies discussed include: • WSG ADAPT • Olympia • Metastatic cdk4/6 inhibitor updates • B42 studies • EA1131 • Neo TALA In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Click here to obtain your 1.50 CME credit: https://bit.ly/3zvDPaU Learners notification: https://bit.ly/2THKeQ4 If you have questions regarding this enduring material activity, please contact us at certificates@amedcoemail.com.

From our 2021 Evolution Kansas City Conference, a meetings for women treating women's cancers, we bring you a session on PreVivor gene carrier identified via cascade testing. Expert panelists include; Lauren Nye, MD, Jamie Wagner, DO, Onalisa Winblad, MD and Katie Nelson, MS, CGC from KU Cancer Center, and Dineo Khabele, MD from Siteman Cancer Center. This multidisciplinary panel dives into specific previvor cases and covers the categories of breast density, supplemental screening, genetic assessments, HBOC syndrome, Risk-reducing bilateral-salpingo-oophrectomy (BSO) +/- hysterectomy, SEE-FIM Protocol, Cascade Testing, and more. To obtain CME/CE credits and MOC points you must watch the full 2021 Evolution Kansas City Conference Playlist, click here to view all sessions: https://bit.ly/39ZoHaB Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.